FY2026 Earnings Forecast for DFTX Issued By Lifesci Capital

Definium Therapeutics, Inc. (NASDAQ:DFTX) – Lifesci Capital upped their FY2026 earnings estimates for shares of Definium Therapeutics in a research note issued on Monday, June 22nd. Lifesci Capital analyst F. Brisebois now anticipates that the company will earn ($2.30) per share for the year, up from their prior forecast of ($2.32). The consensus estimate for Definium Therapeutics’ current full-year earnings is ($2.30) per share. Lifesci Capital also issued estimates for Definium Therapeutics’ Q4 2026 earnings at ($0.54) EPS.

DFTX has been the topic of a number of other research reports. Leerink Partners set a $52.00 price target on shares of Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday. Robert W. Baird boosted their price objective on shares of Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday. Canaccord Genuity Group set a $60.00 price objective on Definium Therapeutics in a report on Monday. Stifel Nicolaus set a $30.00 target price on Definium Therapeutics and gave the stock a “buy” rating in a research report on Thursday, April 16th. Finally, Needham & Company LLC lifted their target price on Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Definium Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $46.08.

Definium Therapeutics Price Performance

Definium Therapeutics stock opened at $36.18 on Wednesday. Definium Therapeutics has a 1 year low of $6.40 and a 1 year high of $39.16. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69. The firm has a 50 day moving average price of $23.28 and a 200 day moving average price of $18.75. The company has a market cap of $3.61 billion, a price-to-earnings ratio of -14.53 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23).

Institutional Investors Weigh In On Definium Therapeutics

Several institutional investors have recently bought and sold shares of DFTX. Boxer Capital Management LLC acquired a new stake in shares of Definium Therapeutics in the third quarter worth $1,928,000. Royce & Associates LP acquired a new position in shares of Definium Therapeutics during the 3rd quarter valued at $955,000. Rosalind Advisors Inc. lifted its holdings in shares of Definium Therapeutics by 78.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock valued at $8,842,000 after acquiring an additional 330,000 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in Definium Therapeutics during the 3rd quarter worth $609,000. Finally, Flagship Harbor Advisors LLC purchased a new stake in Definium Therapeutics during the 4th quarter worth $117,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

More Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium’s Phase 3 Emerge trial for DT120 met the primary endpoint and all key secondary endpoints, reinforcing confidence in the company’s lead depression program. Article: Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder
• Positive Sentiment: Robert W. Baird raised its price target on DFTX and maintained an outperform rating, while Needham also lifted its target and kept a buy rating, signaling improving Wall Street sentiment. Article: Analysts Are Bullish on These Healthcare Stocks: Definium Therapeutics (DFTX), Apogee Therapeutics (APGE)
• Neutral Sentiment: The company plans a webcast to discuss the trial data, which may provide more detail on durability, safety, and next steps for the program. Article: Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
• Negative Sentiment: Definium also announced a proposed $500 million public offering, which could pressure the stock if investors focus on dilution and financing needs. Article: Definium Therapeutics, Inc. Announces Proposed Public Offering

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.